Primary Outcome Measures Compliance of ERAS® guidelines [ Time Frame: 3 months ] Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines Secondary Outcome Measures Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ] Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines Inclusion Criteria Adults female and[…]
Status
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Primary Outcome Measures ORR [ Time Frame: 6 months after the final enrollment ] Objective Response Rate（ORR）according to mRECIST 1.1 standard Secondary Outcome Measures DOR [ Time Frame: 24 months ] Duration of remission DCR [ Time Frame: 24 months ] Disease Control Rate PFS [ Time Frame: 24 months ] Progression Free Survival OS [ Time Frame: 24 months ] Overall Survival AE [ Time Frame: 24 months ] Adverse event SAE [ Time Frame: 24[…]
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Primary Outcome Measures Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma [ Time Frame: 3 months to 4 years ] Assessment by the review of pathologists Inclusion Criteria peritoneal malignant mesothelioma Exclusion Criteria opposition to reuse personnal data
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response[…]
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Primary Outcome Measures Response rate [ Time Frame: Up to 4 years after study activation ] Will be compared between arms. Secondary Outcome Measures Major pathologic response rate [ Time Frame: Up to 3 years ] The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square[…]
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)
Primary Outcome Measures To evaluate the efficacy of atezolizumab in patients with MPM in terms of DFS [ Time Frame: 12 weeks ] DFS, defined as the time from initiation of study treatment to first recurrence of disease or death for any cause, whichever occurs first. Secondary Outcome Measures To evaluate the safety of[…]
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)
Primary Outcome Measures To evaluate the efficacy of the treatment [ Time Frame: From the date of randomization to the date of last follow up, assessed up to 24 months ] To determine the efficacy of M7824 in terms of the Progression Free Survival (PFS) assessed by the investigator according to the modified Response[…]
UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)
This is a single arm, prospective, interventional, multicenter phase 2 study of the combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer (NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥ 1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Primary Outcome Measures Objective response rate (ORR) [ Time Frame: Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose. ] Objective response rate (ORR), defined as the proportion of participants who have a confirmed complete response (CR) or[…]
